logo

業績一覧

講　演

  1. 長島文夫：高齢者前立腺癌治療 監視療法からCRPCまで 高齢者における癌治療について 本邦における老年腫瘍学．第107回日本泌尿器科学会総会，名古屋，2019年4月18日.
  2. Furuse J: Up-To-Date systemic treatments for hepatocellular carcinoma. 8th International Forum of the Japanese Society of Gastroenterology. 第105回日本消化器病学会総会，金沢，2019年5月9日.
  3. 岡野尚弘，松木亮太，土岐真朗，立石秀勝，渡邉俊介，鈴木裕，柴原純二，阪本良弘，杉山政則，古瀬純司：Borderline resectable膵癌に対する術前治療としてのゲムシタビン+ナブパクリタキセル療法のfeasibility試験．第105回日本消化器病学会総会，金沢，2019年5月10日．
  4. 古瀬純司 : 最新の膵癌治療の動向－薬物療法の進歩．第22回湖南・東近江消化器カンファレンス，近江八幡，2019年5月16日．
  5. 古瀬純司：MSI-High膵癌・胆道癌における新たな治療戦略－免疫チェックポイント阻害剤登場. Oncologyインターネット講演会，東京，2019年5月23日．
  6. Nara S, Shimada K, Uesaka K, Konish M, Ohtsuka M, Hirono S, Unno M, Yanagimoto H, Nomura T, Sata N, Wada H, Hatano E, Sakamoto H, Ohta T, Fujino Y, Morinaga S, Tahara M, Ambo Y, Ohta K, Fujii T, Shirakawa H, Nagano H, Miyamoto A, Takeda K, Sugimachi K, Furuse J : The assessment of preoperative diagnostic accuracy of multidetector-row computed tomography (MDCT) for resectable biliary tract cancer- multi-institutional validity study in Japan. Digestive Disease Week 2019, USA, May 18th-21st, 2019.
  7. Shibasaki-Hirano H, Usukura C, Katsumata S, Hirahara Y, Hirano R, Yokokawa A, Maesono T, Kawai K, Nishioka M, Kobayashi T, Okano N, Nagashima F, Furuse J : Simultaneous measurement of regorafenib and its metabolites in human plasma using HPLC and pharmacokinetics in Japanese patients. 日本TDM学会学術集会，東京，2019年5月25-26日．
  8. Kudo M, Motomura K, Wada Y, Inaba Y, Sakamoto Y, Kurosaki M, Umeyama Y, Kamei Y, Yoshimitsu J, Fujii Y, Aizawa M, Robbins PB, Furuse J: First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: results from a phase 1b trial (VEGF Liver 100). ASCO2019, USA, June 3rd, 2019.
  9. 古瀬純司 : 肝細胞癌に対する薬物療法：最近の話題と今後の展望．第31回日本肝胆膵外科学会学術集会，高松，2019年6月14日．
  10. Furuse J, Kawakami H, Mizukami T, Ozaka M, Okano N, Ueno M, Hijioka S, Ueno T, Naito Y, Nakajima TE: International clinical practice guidelines for metastatic liver tumors: Interim report. The 31st Meeting of Japan Society of Hepato-Biliary-Pancreatic Surgery, 高松，2019年6月14日．
  11. 長島文夫：高齢者がん診療の考え方　高齢者機能評価と意思決定支援を含めて．第1回地域がん医療連携研修会，横浜，2019年6月25日．
  12. 池田公史，工藤正俊，奥坂拓志，本村健太，大野泉，森本学，瀬尾智，和田幸之，佐藤新平，山下竜也，古川正幸，新槇剛，灘野成人，大川和良，藤井博文，工藤敏啓，古瀬純司，髙井弘基，本間剛介，吉川麗月，Andrew X. Zhu：ソラフェニブ後のAFP高値進行肝細胞癌に対するラムシルマブ：2つの国際共同無作為化第3相試験の併合解析における日本人患者の有効性と安全性．第20回日本肝がん分子標的治療研究会，長崎，2019年6月29日．
  13. 古瀬純司，泉並木，工藤正俊，本村健太，薮下和久，稲葉吉隆，片村嘉男，近藤泰輝：切除不能な肝細胞癌患者に対するレンバチニブ投与の多施設観察研究-中間報告-．第20回日本肝がん分子標的治療研究会，長崎，2019年6月29日．
  14. 古瀬純司 : バイオマーカー．（特別発言）第55回日本肝癌研究会，東京，2019年7月5日.
  15. 古瀬純司 : 膵癌の薬物療法-これまでとこれから．第50回日本膵臓学会大会，東京，2019年7月12-13日.
  16. 古瀬純司，福冨晃，水野伸匡，尾阪将人，井岡達也，奥坂拓志 : 切除不能膵癌に対する化学療法．膵癌診療ガイドライン2019．膵癌診療の進歩値明日への提言．第50回日本膵臓学会大会，東京，2019年7月12-13日．
  17. 庄司広和，工藤千恵，高石官均，高橋直樹，傳田忠道，川上武志，山口研成，古瀬純司，森脇俊和，高野利美，澤田亮一，宮本敬大，今関洋，青木一教，室圭，朴成和：標準治療に不応不耐進行胃癌患者に対するNivoluamb療法のBiomarker研究．第17回日本臨床腫瘍学会学術集会，京都，2019年7月18日．
  18. 津村英隆，森実千種，野村尚吾，高橋秀明，岡野尚弘，水野伸匡，佐竹悠良，辻国広，塩路和彦，浅木彰則，安居幸一郎，宮川浩之，石黒敦，小倉孝，上野誠，飛松和俊，寺島健志，池田公史，奥坂拓志，古瀬純司：Phase II trial of GEMOX for the advanced pancreatic cancer with family/personal history of HBOC related cancer. 第17回日本臨床腫瘍学会学術集会，京都，2019年7月19日.
  19. Morizane C, Ikeda M, Ueno M, Kobayashi S, Ohno I, Kondo S, Okano N, Kimura K, Asada S, Namba Y, Okusaka T, Furuse J: Open-label, phase I study of nivolumab or nivolumab/cisplatin/gemcitabine in patients with unresectable/recurrent biliary tract cancer. 第17回日本臨床腫瘍学会学術集会，京都，2019年7月19日.
  20. Ikeda M, Okuyama H, Okusaka T, Furuse J, Furukawa M, Ohkawa S, Hosokawa A, Kojima Y, Hara H, Murohisa G, Shioji K, Asagi A, Mizuno N, Kojima M, Yamanaka T: Everolimus for advanced pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-based chemotherapy. 第17回日本臨床腫瘍学会学術集会，京都，2019年7月19日．
  21. 岡野尚弘：好中球減少に対するマネジメント．第17回日本臨床腫瘍学会学術集会，京都，2019年7月19日.
  22. 古瀬純司，丸山大，木村綾，中村健一，福田治彦 : JCOGにおける患者参画の取り組みと展望．臨床試験への患者参画．第17回日本臨床腫瘍学会学術集会，京都，2019年7月20日．
  23. 古瀬純司 : 肝細胞癌の治療戦略-薬物療法の動向と今後の展望．第2回Digestive Expert Forum in Osaka，大阪，2019年7月26日．
  24. 長島文夫：高齢者のがん診療の考え方．第28回多摩骨軟部腫瘍研究会，三鷹，2019年8月24日．
  25. Furuse J: Molecular targeted therapy for advanced HCC: review of the clinical trials results. Molecular Targeted Therapy: Regional Difference of Treatment Strategy for Intermediate/Advanced stage HCC Patients in a Era of Multi-Targeted Agents Era. The 10th Asia-Pacific Primary Liver Cancer Expert Meeting. 札幌，2019年8月31日．
  26. 古瀬純司：肝細胞癌の薬物療法ー1次治療から2次治療へのエビデンス．NEXT Web conference，東京，2019年9月4日．
  27. 古瀬純司：肝細胞癌の治療戦略-薬物療法の動向と今後の展望．第15回広島肝胆膵研究会，広島，2019年9月6日.
  28. 佐々木ヱリ，前野聡子，河合桐男，小林敬明，岡野尚弘，北村浩，古瀬純司，長島文夫：がん従事者に対するロボット介護機器のアンケ―ト調査．第4回日本がんサポーティブケア学会学術集会，青森，2019年9月6‐7日．
  29. 前野聡子，佐々木ヱリ，河合桐男，小林敬明，岡野尚弘，北村浩，古瀬純司，長島文夫：高齢がん患者における脆弱性の評価と介入を行った症例～各種ガイドラインの活用．第4回日本がんサポーティブケア学会学術集会，青森，2019年9月6‐7日．
  30. 佐々木哲哉，前野聡子，佐々木ヱリ，長島文夫：殺細胞性抗癌薬の添付文書に掲載される依存症治療薬との薬物間相互作用の評価．第4回日本がんサポーティブケア学会学術集会，青森，2019年9月6‐7日．
  31. 古瀬純司：膵癌化学療法の進歩と期待．第164回福岡膵懇話会学術講演会，福岡，2019年9月11日．
  32. 長島文夫：高齢者のがん薬物治療の考え方．東京都病院薬剤師会臨床薬学研究会，八王子，2019年9月19日．
  33. 古瀬純司：膵がん薬物療法の進歩－がんゲノム医療でどう変わる？．第71回日本消化器画像診断研究会，和歌山，2019年9月21日．
  34. Okano N, Ueno M, Morizane C, Yamanaka T, Ojima H, Ozaka M, Sasaki M, Takahara N, Kobayashi S, Morimoto M, Hosoi H, Nakai Y, Ikeda M, Maeno S, Nagashima F, Okusaka T, Furuse J : Multicenter phase II trial　of　axitinib　monotherapy　for　advanced　biliary　tract　cancer　refractory　to　gemcitabine-based chemotherapy. ESMO2019, Spain, September 27th-October 1st, 2019.
  35. Hashimoto Y, Hijioka S, Hirooka Y, Ohno E, Ioka T, Kobahashi S, Okusaka T, Maruki Y, Yashika J, Ashida R, Furuse J, Ikeda M, Kasuya H, Tanaka M, Ueno M : Results from phase I study of the oncolytic viral immunotherapy agent Canerpaturev (C-REV) in combination with gemcitabine plus nab-paclitaxel as first-line treatment of unresectable pancreatic cancer. ESMO2019, Spain, September 27th-October 1st, 2019.
  36. Hijioka S, Ueno M, Ioka T, Hirooka Y, Ohno E, Ozaka M, Okusaka T, Maruki Y, Kobahashi S, Ashida R, Yashika J, Furuse J, Ikeda M, Kasuya H, Tanaka M, Hashimoto Y: Phase I study of the oncolytic viral immunotherapy agent Canerpaturev (C-REV) with S-1 in patients with stage IV pancreatic cancer. ESMO2019, Spain, September 27th-October 1st, 2019.
  37. Okamoto W, Nakamura Y, Shiozawa M, Komatsu Y, Denda T, Hara H, Kagawa Y, Narita Y，Kawakami H, Esaki T, Nishina T, Izawa N, Ando K, Moriwaki T, Kato T, Nagashima F, Satoh T, Nomura S, Yoshino T，Akagi K：Microsatellite Instability Status in Metastatic Colorectal Cancer and Effect of Immune Checkpoint Inhibitors on Survival in MSI-High Metastatic Colorectal Cancer. ESMO 2019，Spain，September 27th- October 1st，2019．
  38. Kawamoto Y, Nakamura Y, Ikeda M, Bando H, Esaki T, Ueno M, Nishino T, Kagawa Y. Oki E, Denta T, Mizukami T, Tkahashi N, Okano N, Miki I, Sakamoto Y, M.Lefterova, J.Odegaard, Taniguchi H, Morizane C, Yoshino T : Biological difference of tumor mutational burden(TMB)and microsatellite instability(MSI)status in patients with somatic vs. germline BRCA1/2-mutated advanced gastrointestinal(GI)cancers using cell-free DNA(cfDNA)sequencing analysis in the GOZILA study. ESMO 2019，Spain，September 27th- October 1st，2019．
  39. 古瀬純司，奥坂拓志，小西大，山崎秀哉：胆道癌診療ガイドライン改訂のポイント：胆道癌に対する化学療法・放射線療法．第55回日本胆道学会学術集会，名古屋，2019年10月3-4日．
  40. 長島文夫：高齢者のがん医療の考え方．Nagasaki Hematology Seminar，長崎，2019年10月4日.
  41. 長島文夫：高齢者のがん診療の考え方：第多摩エリアの化学療法を考える会．調布，2019年10月11日．
  42. Nakajima TE, Mizukami T, Takeda H, Kawakami H, Okano N, Ueno M, Hijioka S, Ozaka M, Ueno T, Naito Y, Furuse J: Chemotherapy. International clinical practice guidelines for metastatic liver tumors. 第57回日本癌治療学会学術集会，福岡，2019年10月24日．
  43. 長島文夫，岡野尚弘，河合桐男，前園知宏，西岡真理子，杉浦ちとせ，小林敬明，水谷友紀,古瀬純司：高齢者に対するがん治療の適応と限界：日本における老年腫瘍学の現状．第57回日本癌治療学会学術集会，福岡，2019年10月24日.
  44. 中島貴子，水上拓郎，武田弘幸，川上尚人，岡野尚弘，上野誠，肱岡範，尾坂将人，上野貴之，内藤陽一，古瀬純司：転移性肝腫瘍国際診療ガイドライン中間報告．第57回日本癌治療学会学術集会，福岡，2019年10月24日.
  45. 古瀬純司：がん腫別に考える体重減少とその要因：膵癌．第57回日本癌治療学会学術集会，福岡，2019年10月25日．
  46. 西岡真理子，古瀬純司：当院のゲムシタビン不応膵癌に対するゲムシタビン＋ナブパクリタキセル併用療法の治療成績．第57回日本癌治療学会学術集会，福岡，2019年10月25日.
  47. Furuse J, Okano N, Ueno M, Kawai M, Yamanaka T, Yamaue H: Conversion Surgery for unresectable Pancreatic Cancer. 第57回日本癌治療学会学術集会，福岡，2019年10月26日.
  48. 河合桐男，古瀬純司 : 50%以上の肝占拠病変もしくは門脈本幹浸潤Vp4の肝細胞癌にレンバチニを使用した3例．第57回日本癌治療学会学術集会，福岡，2019年10月26日．
  49. 前園知宏，古瀬純司：切除可能膵癌への術後補助療法S-1後に再発した切除不能膵癌へのFOLFIRINOX療法の検討．第57回日本癌治療学会学術集会，福岡，2019年10月26日．
  50. 長島文夫：高齢者がん診療の考え方―国内外のガイドラインを参考に―．第15回GI-Net Club学術講演会，大阪，2019年10月26日．
  51. 長島文夫：高齢者のがん薬物療法の考え方―国内外のガイドラインを参考に―．第4回栃木県がん領域薬剤師フォーラム，宇都宮，2019年10月28日．
  52. 長島文夫：高齢者のがん治療．杏林大学公開講演会，三鷹，2019年11月2日．
  53. Hiraoka Y, Nakamura Y, Kawamoto Y, Ikeda M, Bando H, Esaki T, Ueno M, Nishina T, Kagawa Y, Oki E, Denda T, Migita O, Takahashi N, Okano N, Ogata Y, Lefterova M, Odegaaed J, Taniguchi H, Morizane C, Yoshino T, Kuwata T: Purative Germline BRCA1/2 Mutations in Patients(pts)with Advanced Gastrointestinal(GI)Cancers Using Circulating Cell-Free Tumor DNA(cfDNA) Analysis in the GOZAILA study. NSGC38th Annual Conference, USA, November 5th-8th, 2019.
  54. Maesono T, Nishioka M, Sugiura C, Kawai K.Okano N, Kobayashi T, Mizutani T, Nagashima F, Shibahara J, Sakamoto Y, Furuse J: A Case of Unresectable Pancreatic Cancer with BRCA1 Gene Mutation Effectively Worked by modified FOLFIRINOX after Gemcitabine plus nab-Paclitaxel Refractory. APA-JPS joint meeting in 2019, USA, November 7th, 2019.
  55. Matsuoka A, Tsubata Y, Mizutani T, Takahashi M, Shimodaira H, Hamamoto Y, Nagashima F, Ando Y：Development and Distribution of the Japanese Edition of SIOG Educational Materials, 19th Conference of the international Society of Geriatric Oncology, Switzerland, November 14th-16th, 2019.
  56. 黒澤貴志，岡野尚弘，松木亮太，西岡真理子，前園知宏，河合桐男，小林敬明，鈴木裕，長島文夫，柴原純二，阪本良弘，古瀬純司：切除不能膵癌に対するconversion surgery後の再発と治療選択について．JDDW2019，第61回日本消化器病学会大会，神戸，2019年11月21日.
  57. 古瀬純司：肝細胞がんにおける薬物療法－最近の動向．JDDW2019，第23回日本肝臓学会大会，神戸，2019年11月22日．
  58. 岡野尚弘：胆膵癌化学療法最新の知見．第27回日本消化器関連学会週間，神戸，2019年11月23日.
  59. 古瀬純司：がんゲノム医療の現状と動向ー今何ができるか．多摩エリア大腸がんeセミナー，立川，2019年11月28日．
  60. 坂田好美，古瀬純司：VTE Expert meeting in MITAKA，三鷹，2019年11月29日．
  61. Ioka T, Nakamori S, Sugimori K, Kanai M, Ikeda M, Ozaka M, Furukawa M, Okusaka T, Kawabe K, Furuse J, Komatsu Y, Ishii H, Sato A, Shimizu S, Chugh P, Rui Tang R, Seraj J, Ueno M: Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC). ESMO-Asia 2019, Singpore, November 22nd-24th, 2019.
  62. 古瀬純司：膵・胆道癌 薬物療法の最近の動向とJCOG肝胆膵グループの取り組み．第7回関西肝胆道オンコロジーグループ学術集会，山口，2019年12月21日．
  63. 古瀬純司：膵がん治療の最前線－がんゲノム医療は膵がん治療を変える．パンキャンジャパン膵臓がん勉強会クリスマス・スペシャル，東京，2019年12月22日．
  64. 古瀬純司，吉岡祐亮：ゲノム医療の時代におけるリキッドバイオプシーの役割．第4回リキッドバイオプシー研究会，東京，2020年1月17-18日.
  65. Nakamura Y, Taniguchi H, Bando H, Kato K, Esaki T, Komatsu Y, Takahashi N, Ueno M, Kagawa Y, Nishina T, Kato T, Yamamoto Y, Furuse J, Denda T, Kawakami H, Oki E, Sunakawa Y, Satoh T, Yoshino T, Ohtsu A: Utility of Circulating Tumor DNA (ctDNA) versus Tumor Tissue Clinical Sequencing for Enrolling Patients with Advanced Gastrointestinal (GI) Cancer to Matched Clinical Trials: SCRUM-Japan GI-SCREEN and GOZILA Combined Analysis. 2020 Gastrointestinal cancers symposium, USA, January 23rd-25th, 2020.
  66. Morizane C, Ueno M, Ioka T, Tajika M, Ikeda M, Yamaguchi K, Hara H, Yabusaki H, Miyamoto A, Iwasa S, Muto M, Takashima T, Minashi K, Komatsu Y, Nishina T, Nakajima TE, Sahara T, Funasaka S, Yashiro M, Furuse J: Expansion part of phase 1 study of E7090 in patients with cholangiocarcinoma harboring FGFR2 gene fusion and with gastric cancer harboring FGFR2 gene amplification or FGFR2 protein high expression. 2020 Gastrointestinal cancers symposium, USA, January 23rd-25th, 2020.
  67. Yoshida Y, Fukutomi A, Ueno M, Mori K, Watanabe K, Ohba A, Kobayashi S, Furuta M, Tsujimoto A, Osaka M, Okano N, Yane K, Umemoto K, Kawamoto Y, Terashima T, Tsumura H, Doi K, Shioji K, Asagi A, Furuse J: Efficacy of chemotherapy for patients with unresectable or recurrent pancreatic adenosquamous carcinoma: a multicenter retrospective analysis. 2020 Gastrointestinal cancers symposium, USA, January 23rd-25th, 2020.
  68. Todaka A, Nara S, Motoi F, Morinaga S, Hama N, Higuchi R, Konishi M, Shirakawa H, Tsumura H, Okuyama H, Matsui H, Shioji K, Sugimachi K, Asagi A, Mizuno N, Fukutomi A, Furuse J: Multicenter retrospective observational study of pancreatic cancer with positive peritoneal lavage cytology intended for surgical resection. 2020 Gastrointestinal cancers symposium, USA, January 23rd-25th, 2020.
  69. Bekaii-Saab TS, Valle JW, Van Cutsem E, Rimassa L, Furuse J, Ioka T, Melisi D, Macarulla T, Bridgewater JA, Wasan HS, Borad MJ, Lihou CF, Zhen H, Luis Féliz L, Asatiani E, Jiang P, Vogel A: FIGHT-302: Phase 3 Study of First-line Pemigatinib Versus Gemcitabine Plus Cisplatin for Cholangiocarcinoma With FGFR2 Fusions or Rearrangements. 2020 Gastrointestinal cancers symposium, USA, January 23rd-25th, 2020.
  70. Borad MJ, Bridgewater JA, Morizane C, Shroff RT, Oh DY, Moehler M, Furuse J, Benhadji KA, He Y, Valle JW: An open-label, randomized phase 3 study of futibatinib (TAS-120) versus gemcitabine-cisplatin chemotherapy as first-line treatment for patients with advanced cholangiocarcinoma harboring fibroblast growth factor receptor 2 gene rearrangements (FOENIX-CCA3). 2020 Gastrointestinal cancers symposium, January 23rd-25th, 2020.
  71. 古瀬純司：膵がん薬物療法の進歩－がんゲノム医療でどう変わる?．T-CORE college 2020, 仙台，2020年2月8日.
  72. Furuse J: Patient and Public Involvement, PPI. JCOG-EORTC symposium, Tokyo, February 15th, 2020.
  73. 長島文夫：高齢がん患者の治療選択について考える. 第34回日本がん看護学会学術集会，東京，2020年2月22日.

論　文

欧文

  1. Kudo M1, Ueshima K1, Ikeda M2, Torimura T3, Tanabe N4, Aikata H5, Izumi N6, Yamasaki T7, Nojiri S8, Hino K9, Tsumura H10, Kuzuya T11, Isoda N12, Yasui K13, Aino H14, Ido A15, Kawabe N16, Nakao K17, Wada Y18, Yokosuka O19, Yoshimura K20, Okusaka T21, Furuse J, Kokudo N22, Okita K23, Johnson PJ24, Arai Y21(1Kindai University Faculty of Medicine, 2National Cancer Center Hospital East, 3Kurume University School of Medicine, 4National Hospital Organisation Sendai Medical Center, 5Hiroshima University, 6Musashino Red Cross Hospital, 7Yamaguchi University Graduate School of Medicine, 8Nagoya City University Graduate School of Medical Sciences, 9Kawasaki Medical School, 10Hyogo Cancer Center, 11Nagoya University Graduate School of Medicine, 12Jichi Medical University, 13Kyoto Prefectural University of Medicine, 14Social Insurance Tagawa Hospital, 15Kagoshima University Graduate School of Medical and Dental Sciences, 16Fujita Health University School of Medicine, 17Nagasaki University Graduate School of Biomedical Sciences, 18National Hospital Organization Kyushu Medical Center, 19Chiba University, 20Hiroshima University, 21National Cancer Center Hospital, 22National Center for Global Health and Medicine, 23Shunan Memorial Hospital, 24University of Liverpool, TACTICS study group): Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut 2019. DOI: 10.1136/gutjnl-2019-318934. [Epub ahead of print]
  2. Koyama T1, Shimizu T1, Iwasa S1, Fujiwara Y1, Kondo S1, Kitano S1, Yonemori K1, Shimomura A1, Iizumi S1, Sasaki T2, Furuse J, Yamamoto N1(1National Cancer Center Hospital, 2Eisai): First-in-human phase I study of E7090, a novel selective FGFR inhibitor, in patients with advanced solid tumors. Cancer Sci 111(2): 571-579, 2019.
  3. Ueno M1, Morizane C2, Ikeda M3, Okusaka T2, Ishii H4, Furuse J (1Kanagawa Cancer Center,2National Cancer Center Hospital, 3National Cancer Center Hospital East, 4Chiba Cancer Center): A review of changes to and clinical implications of the eighth TNM classification of hepatobiliary and pancreatic cancers. Jpn J Clin Oncol 249(12): 1073-1082, 2019.
  4. Morizane C1, Okusaka T1, Mizusawa J1, Katayama H2, Ueno M3, Ikeda M4, Ozaka M5, Okano N, Sugimori K6, Fukutomi A7, Hara H8, Mizuno N9, Yanagimoto H10, Wada K11, Tobimatsu K12, Yane K13, Nakamori S14, Yamaguchi H15, Asagi A16, Yukisawa S17, Kojima Y18, Kawabe K19, Kawamoto Y20, Sugimoto R21, Iwai T22, Nakamura K23, Miyakawa H24, Yamashita T25, Hosokawa A26, Ioka T27, Kato N28, Shioji K29, Shimizu K30, Nakagohri T31, Kamata K32, Ishii H23, Furuse J (1National Cancer Center Hospital, 2Kanagawa Cancer Center, 3National Cancer Center Hospital East, 4Cancer Institute Hospital of Japanese Foundation for Cancer Research, 5Yokohama City University Medical Center, 6Shizuoka Cancer Center, 7Saitama Cancer Center, 8Aichi Cancer Center Hospital, 9 Kansai Medical University Hospital, 10Teikyo University School of Medicine, 11Department of Internal Medicine Kobe University Graduate School of Medicine, 12Teine Keijinkai Hospital, 13 National Hospital Organization Osaka National Hospital, 14Jichi Medical University, 15National Hospital Organization Shikoku Cancer Center, 16Tochigi Cancer Center, 17National Center for Global Health and Medicine, 18Kyushu University, 19Hokkaido University Hospital, 20 National Hospital Organization Kyushu Cancer Center, 21Kitasato University Hospital, 22Chiba Cancer Center, 23Sapporo Kousei General Hospital, 24Kanazawa University, 25University of Toyama, 26Osaka International Cancer Institute, 27Chiba University, 28Niigata Cancer Center Hospital, 29Tokyo Women’s Medical University, 30Tokai University School of Medicine, 31Tokai University School of Medicine, 32Kindai University Faculty of Medicine) : Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: The FUGA-BT (JCOG1113) Randomized Phase III Clinical Trial. Ann Oncol 30(12):1950-1958, 2019.
  5. Hamauchi S1, Furuse J, Takano T2, Munemoto Y3, Furuya K4, Baba H5, Takeuchi M6, Choda Y7, Higashiguchi T8, Naito T9, Muro K10, Takayama K11, Oyama S12, Takiguchi T12, Komura N12, Tamura K13(1Shizuoka Cancer Center, 2Toranomon Hospital, 3Fukui-ken Saiseikai Hospital, 4Hokkaido Hospital, 5Kumamoto University, 6Nagaoka Red Cross Hospital, 7Hiroshima Citizens Hospital, 8Fujita Health University School of Medicine, 9Shizuoka Cancer Center, 10Aichi Cancer Center Hospital, 11Kyoto Prefectural University of Medicine, 12Ono Pharmaceutical Company, 13Fukuoka University) : A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia. Cancer 125(23):4294-4302, 2019.
  6. Furuse J: Paradigm shifting of systemic chemotherapy for unresectable pancreatic cancer in Japan. J Clin Med 8(8): 1170, 2019.
  7. Hamaguchi T1, Denda T2, Kudo T3, Sugimoto N4, Ura T5, Yamazaki K6, Fujii H7, Kajiwara T8, Nakajima TE9, Takahashi S10, Otsu S11, Komatsu Y12, Nagashima F, Moriwaki T13, Esaki T14,Sato T15, Itabashi M16, Oki E17, Sasaki T18, Chiron M19, Yoshino T20 (1National Cancer Center Hospital, 2Chiba Cancer Center, 3Osaka University Graduate School of Medicine, 4Osaka Medical Center for Cancer and Cardiovascular Disease, 5Aichi Cancer Center Hospital, 6Shizuoka Cancer Center, 7Jichi Medical University Hospital, 8Shikoku Cancer Center, 9 Marianna University School of Medicine Hospital, 10Tohoku University Hospital, 11Oita University Hospital, 12Hokkaido University Hospital, 13University of Tsukuba Hospital. 14National Kyushu Cancer Center, 15Kitasato University East Hospital, 16Tokyo Women’s Medical University Hospital, 17Kyushu University Hospital, 18Sanofi K. K, 19Sanofi, 20National Cancer Center Hospital East): Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer. Cancer Sci 110(11): 3565-3572, 2019.
  8. Ueno M1, Nagashima F, Ueno H2, Ikeda M3, Ohkawa S1, Mizuno N4, Ioka T5, Omuro Y6, Nakajima TE7 Furuse J (1Kanagawa Cancer Center, 2National Cancer Center Hospital, 3National Cancer Center Hospital East, 4Aichi Cancer Center Hospital, 5Osaka International Cancer Institute, 6Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 7 Marianna University School of Medicine Hospital) : Phase I/II study: experience with the late onset of acute pancreatitis after the start of chemotherapy with gemcitabine plus nab-paclitaxel for metastatic pancreatic cancer. Intern Med 58(20): 2957-2962, 2019.
  9. Kudo M1, Ikeda M2, Ueshima K1, Sakamoto M3, Shiina S4, Tateishi R2, Hasegawa K5, Furuse J, Miyayama S6, Murakami T7, Yamashita T8, Kokudo N9(1Kindai University Faculty of Medicine, 2National Cancer Center Hospital East, 3Keio University School of Medicine, 4Juntendo University, 5University of Tokyo, 6Fukuiken Saiseikai Hospital, 7Kobe University Graduate School of Medicine, 8Kanazawa University, 9National Center for Global Health and Medicine) : Response evaluation criteria in cancer of the liver version 5 (RECICL 2019 revised version). Hepatol Res 49(9): 981-989, 2019.
  10. Ueno M1, Ikeda M2, Morizane C3, Kobayashi S1, Ohno I2, Kondo S3, Okano N, Kimura K4, Asada S4, Namba Y4, Okusaka T3, Furuse J (1Kanagawa Cancer Center, 2National Cancer Center Hospital East, 3National Cancer Center Hospital,4Ono Pharmaceutical Co, Ltd): Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol Hepatol :4(8):611-621, 2019.
  11. Hidaka H1, Izumi N2, Aramaki T3, Ikeda M4, Inaba Y5, Imanaka K6, Okusaka T7, Kanazawa S8, Kaneko S9, Kora S10, Saito H11, Furuse J, Matsui O12, Yamashita T9, Yokosuka O13, Morita S14, Arioka H15, Kudo M16, Arai Y7(1Kitasato University School of Medicine, 2Musashino Red Cross Hospital, 3Shizuoka Cancer Center, 4National Cancer Center Hospital East, 5Aichi Cancer Center Hospital, 6Osaka International Cancer Institute,7National Cancer Center Hospital, 8Okayama University Medical School, 9Kanazawa University Hospital, 10Fukuoka University, 11Asahikawa Kosei General Hospital, 12Kanazawa University Graduate School of Medical Science, 13Chiba University, 14 Kyoto University Graduate School of Medicine, 15Yokohama Rosai Hospita, 16Kindai University Faculty of Medicine)：Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL). Med Oncol 36(6): 52, 2019.
  12. Yamamoto N1, Ryoo BY2, Keam B3, Kudo M4, Lin CC5, Kunieda F6, Ball HA6, Moran D6, Komatsu K7, Takeda K6, Fukuda M7, Furuse J, Morita S8, Doi T9(1National Cancer Center Hospital, 2University of Ulsan, 3Seoul National University Hospital, 4Kindai University, 5 National Taiwan University Hospital, 6Astellas Pharma Global Development, Inc, 7Astellas Pharma, 8Kyoto University, 9National Cancer Center Hospital East) : A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid Invest New Drugs, 2019. DOI: 10.1007/s10637-019-00780-w. [Epub ahead of print]
  13. Kaibori M1, Yoshii K2, Yokota I2, Hasegawa K3, Nagashima F, Kubo S4, Kon M5, Izumi N6, Kadoya M7, Kudo M8, Kumada T9, Sakamoto M10, Nakashima O11, Matsuyama Y12, Takayama T13, Kokudo N14(1Kansai Medical University, 2Kyoto Prefectural University of Medicine, 3 The University of Tokyo , 4Osaka City University Graduate School of Medicine , 5Musashino Red Cross Hospital, 6Shinshu University School of Medicine , 7Kinki University School of Medicine , 8Ogaki Municipal Hospital , 9Keio University School of Medicine, 10Kurume University Hospital,11School of Public Health University of Tokyo, 12 Nihon University School of Medicine, 13National Center for Global Health and Medicine, Liver Cancer Study Group of Japan) : Impact of Advanced Age on Survival in Patients Undergoing Resection of Hepatocellular Carcinoma: Report of a Japanese Nationwide Survey. Ann Surg 269(4): 692-699, 2019.
  14. Mizutani T1, Nakamura K1, Fukuda H1, Ogawa A2, Hamaguchi T3, Nagashima F (1 National Cancer Center Hospital, 2National Cancer Center Hospital East, 3Saitama Medical University International Medical Center, Geriatric Study Committee/Japan Clinical Oncology Group) Geriatric Research Policy: Japan Clinical Oncology Group (JCOG) policy. Japanese Journal of Clinical Oncology 49(10) :901-910, 2019.
  15. Okusaka T1, Nakamura M2, Yoshida M3, Kitano M4, Uesaka K5, Ito Y6, Furuse J, Hanada K7, Okazaki K8 (1National Cancer Center Hospital, 2Kyushu University, 3International University of Health and Welfare, 4Wakayama Medical University, 5Shizuoka Cancer Center, 6Showa University School of Medicine, 7JA Onomichi General Hospital, 8Kansai Medical University) Committee for Revision of Clinical Guidelines for Pancreatic Cancer of the Japan Pancreas Society: Clinical Practice Guidelines for Pancreatic Cancer 2019 From the Japan Pancreas Society: A Synopsis. Pancreas 49(3) :326-335, 2020.
  16. Kudo M1, Okusaka T2, Motomura K3, Ohno I4, Morimoto M5, Seo S6, Wada Y7, Sato S8, Yamashita T9, Furukawa M10, Aramaki T11, Nadano S12, Ohkawa K13, Fujii H14, Kudo T15, Furuse J, Takai H16, Homma G16, Yoshikawa R16, Zhu AX17(1Kindai University Faculty of Medicine, 2National Cancer Center Hospital, 3Aso Iizuka Hospital, 4National Cancer Center Hospital East, 5Kanagawa Cancer Center, 6Kyoto University, 7National Hospital Organization Kyushu Medical Center, 8Kyoundo Hospital, Sasaki Institute, 9Kanazawa University, 10National Hospital Organization Kyushu Cancer Center, 11Shizuoka Cancer Center Hospital,12National Hospital Organization Shikoku Cancer Center, 13Osaka International Cancer Institute, 14Jichi Medical University, 15Osaka University, 16Eli Lilly Japan K.K, 17Massachusetts General Hospital Cancer Center) : Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial. J Gastroenterol 2020. DOI:10.1007/s00535-020-01668-w. [Epub ahead of print]
  17. Okuyama H1,2, Ikeda M2, Okusaka T3, Furukawa M4, Ohkawa S5, Hosokawa A6, Kojima Y7, Hara H8, Murohisa G9, Shioji K10, Asagi A11, Mizuno N12, Kojima M13, Yamanaka T14, Furuse J (1Kagawa University, 2National Cancer Center Hospital East, 3National Cancer Center Hospital, 4National Hospital Organization Kyushu Cancer Center, 5Kanagawa Cancer Center, 6Faculty of Medicine University of Toyama, 7National Center for Global Health and Medicine, 8Saitama Cancer Center, 9Seirei Hamamatsu General Hospital, 10Niigata Cancer Center Hospital, 11National Hospital Organization Shikoku Cancer Center, 12Aichi Cancer Center Hospital, 13National Cancer Center, 14Yokohama City University Graduate School of Medicine) : A phase II trial of everolimus in patients with advanced pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-containing chemotherapy (NECTOR trial). Neuroendocrinology 2020. DOI: 10.1159/000505550. [Epub ahead of print]
  18. Naito Y1, Mishima S1, Akagi K2, Igarashi A3, Ikeda M1, Okano S1, Kato S4, Takano T5, Tsuchihara K1, Terashima K6, Nishihara H7, Nishiyama H8, Hiyama E9, Hirasawa A10, Hosoi H11, Maeda O12, Yatabe Y13, Okamoto W9, Ono S14, Kajiyama H12, Nagashima F, Hatanaka Y15, Miyachi M11, Kodera Y12, Yoshino T1, Taniguchi H1（1National Cancer Center Hospital East, 2Saitama Cancer Center, 3Yokohama City University School of Medicine, 4Juntendo University, 5Tohoku University, 6National Center for Child Health and Development, 7Keio University, 8Tsukuba University, 9Hiroshima University Hospital, 10Okayama University, 11Kyoto Prefectural University of Medicine, 12Nagoya University Hospital, 13National Cancer Center Hospital, 14Jichi Medical University, 15Hokkaido University Hospital）：Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology. Int J Clin Oncol 25(3) :403-417, 2020.
  19. Okusaka T1, Nakamura M2, Yoshida M3, Kitano M4, Uesaka K5, Ito Y6, Furuse J, Hanada K7, Okazaki K8(1National Cancer Center Hospital, 2Kyushu University, 3International University of Health and Welfare, 4Wakayama Medical University, 5Shizuoka Cancer Center, 6Showa University School of Medicine, 7JA Onomichi General Hospital, 8Kansai Medical University, Committee for Revision of Clinical Guidelines for Pancreatic Cancer of the Japan Pancreas Society): Clinical Practice Guidelines for Pancreatic Cancer 2019 From the Japan Pancreas Society: A Synopsis. Pancreas 49(3): 326-335, 2020.
  20. Kitamura H, Nagashima F, Andou M1, Furuse J (1Nagoya University): Feasibility of Continuous Geriatric Assessments as a Prognostic Indicator in Elderly People with Gastrointestinal Cancer. Intern Med 59(1): 15-22, 2020.
  21. Okano N, Naruge D, Kawai K, Kobayashi T, Nagashima F, Endou H1, Furuse J (1J-Pharma Co): First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2020. DOI: 10.1007/s10637-020-00924-3. [Epub ahead of print]
  22. Kitamura H, Nagashima F, Andou M1, Furuse J (1Nagoya University): Feasibility of Continuous Geriatric Assessments as a Prognostic Indicator in Elderly People with Gastrointestinal Cancer. Intern Med 59(1): 15-22, 2020.

和文

  1. 古瀬純司：ラムシルマブとほかの二次治療薬との使い分け．特集／進化する肝細胞癌の薬物療法―2019 Update (Part 1)．肝胆膵 79(2): 344-349, 2019.
  2. 古瀬純司，上野誠1，石井浩2 (1神奈川県立がんセンター・消化器内科，2千葉県がんセンター・治験臨床研究センター)：がん治療における患者参画．医師の立場からの期待．癌と化学療法 46(8): 1230-1234, 2019.
  3. 岡野尚弘，古瀬純司：アテゾリズマブ + ベバシズマブ併用Phase Ib試験のUpdated data. 特集／進化する肝細胞癌の薬物療法―2019 Update (Part 2). 肝胆膵 79(3): 587-591, 2019.
  4. 古瀬純司：レンバチニブ+ ペムブロリズマブ併用療法の第Ⅰb相試験-Updated data. 特集／進化する肝細胞癌の薬物療法―2019 Update (Part 2)．肝胆膵 79(2): 597-600, 2019.
  5. 古瀬純司：胆道癌・膵癌に対する免疫療法の現状と展望．消化器・肝臓内科 6(3): 218-223, 2019.
  6. 古瀬純司：第55回米国臨床腫瘍学会(ASCO2019) meeting report. The Liver Cancer Journal 11(2): 55-58, 2019.
  7. 古瀬純司：術前治療としての化学療法の動向．胆と膵 40(11): 957-961, 2019.
  8. 岡野尚弘，長島文夫，古瀬純司：消化器癌のゲノム医療．杏林医学会誌50(4): 191-197, 2019.

著　書

  1. 古瀬純司（分担執筆）：膵癌．膵腫瘍と嚢胞性膵疾患．消化管・腹膜疾患 肝・胆道・膵疾患. 内科学書改訂第9版. 南学正臣総編集．東京，中山書店，2019．475-479．
  2. 古瀬純司，岡野尚弘（分担執筆）：胆道癌に対するアキシチニブ単独療法の治療開発(B44)．先進医療NAVIGATOR．がん先進医療の最前線．先進医療フォーラム編集．東京，日本医学出版，2019．60-64.
  3. 長島文夫（ガイドライン作成統括委員会副委員長）：高齢者のがん薬物療法ガイドライン．日本臨床腫瘍学会/日本癌治療学会編．東京，南江堂，2019．
  4. 長島文夫（評価委員）：成人・小児進行固形がんにおける臓器横断的ゲノム診療のガイドライン第2版．日本癌治療学会/日本臨床腫瘍学会編．東京，金原出版，2019．
  5. 岡野尚弘（分担執筆）：XELOX(CapeOX)療法．消化器ナーシング. 東京，メディカ出版， p. 35-37.
  6. 岡野尚弘（分担執筆）：アテゾリズマブ＋ベバシズマブ併用phase Ib試験のuodated data.　肝胆膵．東京，アークメディア，2019．587-591.
  7. 岡野尚弘（分担執筆）：GEM＋CDDP (GC). 消化器がん化学療法副作用マネジメントプロのコツ改訂第2版．東京，メジカルビュー社，2019．168-171.
  8. 岡野尚弘（分担執筆）：GEM＋S-1(GS)．消化器がん化学療法副作用マネジメントプロのコツ改訂第2版．東京，メジカルビュー社，2019．172-175.
  9. 岡野尚弘（分担執筆）：胆道癌におけるFGFR遺伝子異常とFGFR阻害薬の開発．胆と膵．東京，医学図書出版，2019．1347-1350.
  10. 岡野尚弘（分担執筆）：肝・胆・膵がんにおけるMSI検査の位置づけ．腫瘍内科．東京，化学評論社，2019．219-224．

報告書

  1. 長島文夫：高齢がん患者に対する簡便で効果的な診療プログラムの開発．厚生労働科学研究費補助金 (がん対策推進総合研究事業)2019年度　分担研究報告書．
  2. 長島文夫：高齢者がん診療指針策定に必要な基盤整備に関する研究．厚生労働科学研究費補助金 (がん対策推進総合研究事業)2019年度　分担研究報告書．

その他

【座長・司会・主催】

  1. 古瀬純司（座長）：外来化学療法カンファレンス. 武蔵野, 2019年4月5日.
  2. 窪田敬一、古瀬純司（司会）: Borderline resectable膵がんに対する治療戦略.金沢, 第105回日本消化器病学会総会, 金沢, 2019年5月10日.
  3. 古瀬純司、廣岡芳樹 (座長)：膵疾患に対する造影超音波検査の有用性と今後の展開. Ultrasonic Week 2019. 日本超音波医学会第92回学術集会, 東京, 2019年5月24日.
  4. 古瀬純司（司会）：ランチョンセミナー. 第108回日本消化器内視鏡学会関東支部例会, 東京, 2019年6月8日.
  5. 古瀬純司 (座長)：Gastric Cancer I-O Seminar in Tama. Lecture. 立川, 2019年6月24日.
  6. 古瀬純司 (座長)：GEP-NET Web Seminar. 東京, 2019年6月26日.
  7. 古瀬純司 (座長)：Colorectal Cancer Conference. 立川, 2019年6月27日.
  8. 古瀬純司、永井英成（司会）: レンバチニブによる新たな肝細胞癌治療ストラテジー. 第20回日本肝がん分子標的治療研究会, 長崎, 2019年6月29日.
  9. 古瀬純司 (司会): ランチョンセミナー 第55回日本肝癌研究会, 東京, 2019年7月5日.
  10. 古瀬純司（司会）: 特別講演 第50回日本膵臓学会大会, 東京, 2019年7月12-13日.
  11. 高折恭一、古瀬純司（司会）: PanCan Award. 第50回日本膵臓学会大会, 東京, 2019年7月12-13日.
  12. Furuse J（司会）: Guidelines for pancreatic cancer, Japan vs. USA. Luncheon Seminar. 第50回日本膵臓学会大会, 東京, 2019年7月12-13日.
  13. 岡崎和一、古瀬純司（司会）: 日本膵臓学会-昨日から明日へ. 第50回日本膵臓学会大会, 東京, 2019年7月12-13日.
  14. 古瀬純司（司会）: 英語発表上達のコツ. 第50回日本膵臓学会大会, 東京, 2019年7月12-13日.
  15. 長島文夫 (司会) : 膵癌に対する内視鏡治療～疼痛・症状緩和を目指して～. 第50回日本膵臓学会大会, 東京, 2019年7月12-13日.
  16. Furuse J, Ueno M(司会) : New evidence of chemotherapy in biliary tract and pancreatic cancers and introduction them to the practice. 第17回日本臨床腫瘍学会学術集会, 京都, 2019年7月19日.
  17. 古瀬純司 （司会）：メディカルセミナー 第17回日本臨床腫瘍学会学術集会, 京都, 2019年7月19日.
  18. Cheng AL, Furuse J (座長) : Sponsored Symposium 2. The role of Systemic Therapy for uHCC. The 10th Asia-Pacific Primary Liver Cancer Expert Meeting, 札幌, 2019年8月31日.
  19. 古瀬純司 (主催)：第50回日本膵臓学会大会　市民公開講座. 東京，2019年8月4日．
  20. 古瀬純司（Opening remarks）： がん包括マネジメントセミナー. 三鷹, 2019年9月18日.
  21. 古瀬純司（司会）: 膵癌診療ガイドライン改訂後のこれからの治療戦略. 高齢者膵癌に対する治療戦略を考える. 第57回日本癌治療学会学術集会, 福岡, 2019年10月24日.
  22. 山本雅一、吉田雅博、古瀬純司（司会）: 転移性肝癌国際診療ガイドライン公聴会. 第57回日本癌治療学会学術集会, 福岡, 2019年10月24日.
  23. 矢永勝彦、古瀬純司: 臓器別シンポジウム Borderline Resectable膵癌に対する治療戦略. 第57回日本癌治療学会学術集会, 福岡, 2019年10月25日.
  24. 古瀬純司（司会）：血管新生阻害薬, 東京, 2019年10月31日.
  25. Furuse J, Brand R（座長）: Mini Symposium IV. Genomics of exocrine pancreatic disorders. APA-JPS joint meeting in 2019, USA, November 7th-9th,2019.
  26. Qin S, FuruseJ, Paark JO: Hepatobiliary-Pancreatic Cancer Session. 7th Federation of Asian Clinical Oncology (FACO) Academic Conference, China, December 6th,2019.
  27. 古瀬純司（司会）：10周年特別企画2．第21回日本肝がん分子標的治療研究会，東京，2020年1月11日．
  28. 古瀬純司、吉岡祐亮（司会）: ゲノム医療の時代におけるリキッドバイオプシーの役割. 第4回リキッドバイオプシー研究会. 東京, 2020年1月17-18日.
  29. 古瀬純司（司会）: Patient and Public Involvement, PPI. JCOG-EORTC symposium. 東京, 2020年2月15日.
  30. 古瀬純司（座長）：がん疼痛セミナー, がん疼痛治療の最前線. 三鷹, 2019年2月28日.

 

【新聞掲載】

  1. 長島文夫：「質問なるほドリ、乳がんになる高齢者って多いの？」にて解説，毎日新聞，2019年8月31日．
  2. 長島文夫：「医療の意思決定、高齢者のがん・後編」にて解説，読売新聞，2019年11月25日．
  3. 長島文夫：「がん5年生存率病期・年代別公表」にて解説，朝日新聞，2019年12月14日．

講　演

  1. 古瀬純司 : 膵・消化管神経内分泌腫瘍の薬物療法-多様な治療をどう使い分ける？．膵・消化管神経内分泌腫瘍を考える,新潟,2018年4月12日.
  2. Furuse J : Adjuvant therapy experience-including S-1. Pancreas 2018, USA, April 26th-28th, 2018.
  3. 古瀬純司 : 肝細胞がんの化学療法ー新時代への展望. LENVIMA-HCC　適応追加記念講演会, 長崎, 2018年5月16日.
  4. 古瀬純司：消化器がんにおけるPrecision Medicine.GI-SCREENと多摩地区の現状と今後.第6回KDOG meeting, 町田, 2018年5月19日.
  5. 古瀬純司：神経内分泌腫瘍に対する薬物療法ー最新の情報と今後の展望.第10回Tohoku-NET WORK, 仙台, 2018年5月26日.
  6. Okano N, Kawai K, Kobayashi T, Nagashima F, Endou H, Furuse J： First-in-human phase I study of JPH203, L-type amino acids transporter 1 inhibitor, in patients with advanced solid tumors. ASCO 2018 annual meeting, USA, June 1st-6th, 2018.
  7. Tsuji Y, Shitara K, Yamanaka T, Denda T, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Okuda H, Asayama M, Akiyoshi K, Kagawa Y, Kato T, Oki E, Ando T, Hagiwara Y, Ohashi A, Yoshino T: REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan—Biomarker analysis. ASCO 2018 annual meeting, USA, June 1st-6th, 2018.
  8. Ueno M, Morizane C, Okusaka T, Mizusawa J, Katayama H, Ikeda M, Ozaka M, Sugimori K, Fukutomi A, Hara H, Mizuno N, Yanagimoto H, Sano K, Tobimatsu K, Yane K, Nakamori S, Sata N, Yukisawa S, Ishii H, Furuse J: Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer: A Japan Clinical Oncology Group study (JCOG1113, FUGA-BT). ASCO 2018 annual meeting, USA, June 1st-6th, 2018.
  9. Kudo M, Ueshima K, Torimura T, Tanabe N, Ikeda M, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Isoda N, Yasui K, Kuzuya T, Okusaka T, Furuse J, Kokudo N, Okita K, Yoshimura K, Arai Y, TACTICS Trial Group: Randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. ASCO 2018 annual meeting, USA, June 1st-6th,2018.
  10. Abou-Alfa GK, Chan SL, Furuse J, Galle PR, Kelley RK, Qin S, Armstrong J, Darilay A, Vlahovic G, Negro A, Sangro B: A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study. ASCO 2018 annual meeting, USA, June 1st-6th, 2018.
  11. Okano N, Kawai K, Kobayashi T, Nagashima F, Endou H, Furuse J: First-in-human

phase I study of JPH203, L-type amino acids transporter 1 inhibitor, in patients with advanced solid tumors. ASCO 2018 annual meeting, USA, June 1st-6th, 2018.

  1. 古瀬純司, 奥坂拓志, 小西大 : 胆道癌診療ガイドライン公聴会. 化学療法. 第30回日本肝胆膵外科学会学術集会, 横浜, 2018年6月7-9日.
  2. 古瀬純司 : 肝細胞癌の分子標的治療：ソラフェニブ単独から多様な治療選択へ. 第30回日本肝胆膵外科学会学術集会, 横浜, 2018年6月7-9日.
  3. Furuse J: The 2nd line chemotherapy in Japan and future perspectives. The 11th International Pancreatic Cancer Conference, Commemorative Lecture of Pin-Wen Lin and 2018 Cancer Biology Symposium, Taiwan, June 8th-10th, 2018.
  4. Furuse J: The experience of FOLFIRINOX in advanced pancreatic cancer. Japanese experience. Satellite Symposium in the 11th International Pancreatic Cancer Conference, Taiwan, June 8th-10th, 2018.
  5. 古瀬純司 : 特別講演.肝細胞がんの薬物療法ー新時代への展望. LENVIMA-HCC AE Management Forum in Dokkyo, 栃木, 2018年6月13日.
  6. 長島文夫 : 高齢者のがん患者を診療するにあたっての考え方. 第60回日本老年医学会学術集会, 京都, 2018年6月16日.
  7. 古瀬純司 : 特別講演.肝細胞がんの薬物療法ー新時代への展望. Lenvatinib適応追加記念講演会, 金沢, 2018年6月21日.
  8. 岡部直太, 小林敬明, 千葉知宏, 大窪泰弘, 古瀬純司, 草間博 : 食道悪性黒色腫に対するnivolumab治療中にリンパ球性下垂体炎を来した剖検症例の一例. 第107回日本病理学会総会, 札幌, 2018年6月21-23日
  9. 長島文夫 ： 高齢者に抗がん剤は効果なし”は本当なのか?. 日本臨床腫瘍学会市民公開講座, 大阪, 2018年6月24日.
  10. 古瀬純司 : 切除不能膵癌における治療方針－conversion surgeryの是非－. 第49回日本膵臓学会, 和歌山, 2018年6月29日.
  11. 岡野尚弘, 西岡真理子, 前園知宏, 河合桐男, 小林敬明, 長島文夫, 古瀬純司 : 遠隔転移を有する膵癌における化学療法によるconversion surgery. 切除不能膵癌における治療方針－conversion surgeryの是非－. 第49回日本膵臓学会, 和歌山, 2018年6月29日.
  12. 古瀬純司 : 切除不能膵癌に対する化学療法-ガイドラインにおける課題. 特別企画2膵癌ガイドラインの諸問題と今後の課題. 第49回日本膵臓学会, 和歌山, 2018年6月29日.
  13. 西岡真理子, 岡野尚弘, 前園知宏, 河合桐男, 小林敬明, 長島文夫, 古瀬純司: FOLFIRINOXとGEM耐性後、GEM+na-PTX療法が奏効した肝転移を伴う膵癌の1例. 第49回日本膵臓学会, 和歌山, 2018年6月29日.
  14. 前園知宏, 岡野尚弘, 西岡真理子, 河合桐男, 小林敬明, 長島文夫, 古瀬純司: GEM+nab-PTX不応後にmodified FOLFIRINOXが著効したBRCA1遺伝子変異を有した切除不能膵癌の1例. 第49回日本膵臓学会, 和歌山, 2018年6月29日.
  15. 山内芳也, 西岡真理子, 前園知宏, 河合桐男, 小林敬明, 岡野尚弘, 長島文夫, 古瀬純司 : 切除不能・再発膵腺扁平上皮癌に対する併用薬物療法施行例の検討. 第49回日本膵臓学会, 和歌山, 2018年6月29日.
  16. 古瀬純司 : 特別講演.肝細胞がんの薬物療法ー新時代への展望.鹿児島LENVIMA-HCC適応追加記念講演会, 鹿児島, 2018年7月4日.
  17. Furuse J, Chan SL, Sangro B, Galle PR, Kelley RK, Qin S, Armstrong J, Darilay A, Vlahovic G, Xu Y, Negro A, Abou-Alfa GK, on behalf of the HIMALAYA investigators: HIMALAYA study: a randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC). the 9th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2018), Korea, July 6th-8th, 2018.
  18. Furuse J, Hamauchi S, Takano T, Munemoto Y, Furuya K, Baba H, Takeuchi M, Choda Y, Higashiguchi T, Naito T, Muro K, Takayama K, Tamura K: A multicenter, open-label, uncontrolled study of ONO-7643/anamorelin in cachexia patients with gastrointestinal cancer. 第16回日本臨床腫瘍学会学術集会, 神戸, 2018年7月19-21日.
  19. 山内理海, 設楽紘平, 山中竹春,傳田忠道, 辻靖, 小松嘉人, 小林良充, 古瀬純司, 加藤健志, 沖英次, 安藤高志, 萩原康博, 大橋靖雄, 吉野孝之: REVERCE: Randomized Phase II Study of Regorafenib Followed by Cetuximab Versus the Reverse Sequence for Metastatic Colorectal Cancer Patients Previously Treated with Fluoropyrimidine, Oxaliplatin, and Irinotecan: Quality of Life Analysis. 第16回日本臨床腫瘍学会学術集会, 神戸, 2018年7月19-21日.
  20. 奥坂拓志, 池田公史, 大野泉, 高橋秀明, 近藤俊輔, 森実千種, 古瀬純司 : 肝細胞がん患者を対象としたGPC3, WDRPUH及びNEIL3由来ペプチドワクチンの第1相試験における最終解析. 第16回日本臨床腫瘍学会学術集会, 神戸, 2018年7月19-21日.
  21. 小山隆文, 清水俊雄, 藤原豊, 近藤俊輔, 北野滋久, 米盛勧, 下村昭彦, 飯泉桜, 佐々木達也, 古瀬純司, 山本昇 : 新規FGFR選択的阻害薬E7090の進行固形癌患者を対象とした第1相臨床試験. 第16回日本臨床腫瘍学会学術集会, 神戸, 2018年7月19-21日.
  22. 工藤敏啓, 川本泰之, 奥坂拓志, 高橋秀明, 小林智, 古瀬純司, 伊藤心二, 清水怜, 中村和貴, 鎌田研, 衣斐寛倫, 伊藤直樹, 水野伸匡, 石井浩, 森実千種,吉野孝之 : The Nationwide Cancer Genome Screening Project in Japan SCRUM-Japan GI-SCREEN (GI-SCREEN 2015-01-Non CRC) Advanced Biliary Tract Cancer Cohort. 第16回日本臨床腫瘍学会学術集会, 神戸, 2018年7月19-21日.
  23. 長島文夫, 古瀬純司 : JSMO-SIOG symposium All oncologists are geriatric oncologists Geriatric Oncology in Japan. 第16回日本臨床腫瘍学会学術集会, 神戸, 2018年7月19-21日.
  24. 清水怜, 高橋秀明, 上野誠, 大場彬博, 村中徹人, 須藤研太郎, 岡野尚弘, 水上拓郎, 伊藤心二, 石井浩, 賀川義規, 鎌田研, 工藤敏啓, 森実千種, 吉野孝之 : The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-SCREEN: Advanced Pancreatic Cancer Cohort. 第16回日本臨床腫瘍学会学術集会, 神戸, 2018年7月19-21日.
  25. 山内芳也, 西岡真理子, 前園知宏, 河合桐男, 小林敬明, 岡野尚弘, 成毛大輔, 北村浩, 女屋博昭, 長島文夫, 古瀬純司 : 高齢者膵がんにおけるCTを利用した筋肉の評価と薬物療法の臨床的アウトカムに関する研究. 第16回日本臨床腫瘍学会学術集会, 神戸, 2018年7月19-21日.
  26. 古瀬純司 : 膵がんの基礎知識と治療の最新情報. ONCOLO Meets Cancer Experts eminar, 東京, 2018年7月27日.
  27. 古瀬純司 : 消化器癌化学療法の最新情報. ASCO 2018より. 三鷹キャンサーネット, 三鷹, 2018年8月2日.
  28. 古瀬純司 : 膵・消化管神経内分泌腫瘍の新たな展開ー診断から治療まで. 膵・消化管神経内分泌腫瘍セミナー, 宮崎,2018年8月3日.
  29. 古瀬純司 : 肝細胞がんの薬物療法ー新時代への展望.滋賀LENVIMA適正使用講演会, 草津,2018年8月30日.
  30. 北村浩, 長島文夫, 岡野尚弘, 中澤潤一, 有馬志穂, 古瀬純司 : Gemcitabine baseの化学療法を行った高齢者膵がんにおける有害事象と高齢者機能評価について．第3回日本がんサポーティブケア学会, 福岡, 2018年8月31日.
  31. 前野聡子, 長島文夫, 河合桐男, 前園知宏, 黒澤貴志, 小林敬明, 岡野尚弘, 北村浩, 有馬志穂, 古瀬純司：海外高齢者がん診療ガイドライン活用の工夫 － 認知症をもつがん患者の実地症例から－. 第3回日本がんサポーティブケア学会, 福岡, 2018年8月31日.
  32. Sangro B, Chan SL, Furuse J, Galle PR, Kelley RK, Qin S, Armstrong J, Darilay A, Vlahovic G, Xu Y, Negro A, Abou-Alfa G: A Randomized, Multicenter Phase 3 Study of Durvalumab (D) and Tremelimumab (T) as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma (HCC): HIMALAYA Study. ILCA Annual Conference, UK, September 14th-16th, 2018.
  33. Ueshima K, Kudo M, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Yasui K, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Arai Y and TACTICS study group: Randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. ILCA Annual Conference, UK, September 14th-16th, 2018.
  34. Kobayashi S, Terashima T, Shiba S, Yoshida Y, Yamada I, Iwadou S, Horiguchi S, Takahashi H, Suzuki E, Moriguchi M, Tsuji K, Otsuka T, Asagi A, Kojima Y, Takada R, Ueno M, Morizane C, Mizuno N, Ikeda M, Furuse J: Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and ILCA Annual Conference, UK, September 14th-16th, 2018.
  35. 古瀬純司, 奥坂拓志, 小西大, 山崎秀哉 : 胆道癌診療ガイドライン公聴会. 化学療法、放射線療法. 第54回日本胆道学会学術集会, 千葉, 2018年9月27-28日.
  36. Furuse J: Systemic treatment for advanced HCC－Current status and future perspectives. Taiwan Digestive Disease Week 2018. Taiwan, September 29th-30th, 2018.
  37. 古瀬純司：最新のがん治療：ゲノム医療の幕開け. 杏林大学病院がんセンター「がんと共にすこやかに生きる」講演会シリーズ第4回, 三鷹, 2018年10月13日.
  38. 古瀬純司, 岡野尚弘, 黒澤貴志 : 初診時切除不能膵癌に対するconversion surgery
    －内科の立場から. 第56回日本癌治療学会学術集会, 横浜, 2018年10月18-20日.
  39. Furuse J: Cohort study of patients with initially unresectable pancreatic cancer of conversion surgery after FOLFIRINOX or GEM plus nab-PTX (PC-CURE-1). 6th International Conference of FACO. 第56回日本癌治療学会学術集会, 横浜, 2018年10月18-20日.
  40. Denda T, Shitara K, Yamanaka T, Tsuji Y, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Kato T, Ohashi Y, Yoshino T: REVERCE: A Randomized Phase II of Regorafenib- Cetuximab for mCRC previously treated with chemotherapy: serum protein biomarker analysis. 第56回日本癌治療学会学術集会, 横浜, 2018年10月18日-20日.
  41. Kitamura H, Nagashima F, Andou M, Nakazawa J, Arima S, Okano N, Furuse J: Cancer-Specific Geriatric Assessment(CSGA)を用いた高齢者膵癌化学療法の第二相試験. 第56回日本癌治療学会学術集会, 横浜, 2018年10月18-20日.
  42. Izawa N, Morizane C, Takahashi H, Ueno M, Kawamoto Y, Okano N, Shimizu S, Sudo K, Itoh S, Asagi A, Y. Kagawa, K. Kamata, T. Kudo, S. Nomura, T. Kuwata, S. Fujii, W. Okamoto, K. Shitara, A. Ohtsu, T. Yoshino: The nationwide cancer genome screening project in Japan, SCRUM Japan GISCREEN: Efficient identification of cancer genome alterations in advanced biliary tract cancer. ESMO 2018, Germany, October 19th-23rd, 2018.
  43. Takahashi H, Morizane C, Nomura S, Okano N, Tsuda M, Mizuno N, Satake K, Tsuji K, Shioji K, Ishii H, Yasui K, Miyakawa H, Ishiguro A, Ogura T, Ueno M, Ikeda A, Terashima T, Ikeda M, Okusaka T, Furuse J: Phase II clinical trial of gemcitabine plus oxaliplatin combination therapy (GEMOX) in patients with advanced pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study). ESMO 2018, Germany, October 19th-23rd,2018.
  44. Okuyama H, Ikeda M, Okusaka T, Furuse J, Furukawa M, Ohkawa S, Hosokawa A, Kojima Y, Yamaguchi K, Murohisa G, Shioji K, Ishii H, Mizuno N, Kojima M, Yamanaka T: A phase II study of everolimus in patients with unresectable pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-contained chemotherapy. Germany, ESMO 2018, October 19th-23rd, 2018.
  45. 長島文夫 : 本当!? 「高齢者に抗がん剤は“効果なし?”」. ちゃやまちキャンサーフォーラム2018, 大阪, 2018年10月27日.
  46. 古瀬純司 : 膵癌治療の最前線―エビデンスとプラクティス. 第16回日本消化器外科学会大会, 神戸, 2018年11月1-4日.
  47. 古瀬純司 : 切除不能肝内胆管癌の化学療法―現状と今後の展望. 第16回日本消化器外科学会大会, 神戸, 2018年11月1-4日.
  48. 古瀬純司 : 膵癌の化学療法ー最新の動向と今後の展望. Osaka GI Oncology Forum, 大阪, 2018年11月16日.
  49. 古瀬純司 : 膵癌の化学療法ー最新の動向と今後の展望. 第15回京都消化器癌化学療法研究会, 京都, 2018年11月22日.
  50. FuruseJ: Chemotherapy for unresectable pancreatic cancer－Current status and future perspectives. The 8th Japan-China Hepato-Pancreato-Biliary Symposium,,Tokyo, November 22ed-23rd, 2018.
  51. 古瀬純司 : 膵・胆道癌化学療法の最新情報ーがんゲノム医療の導入は？．第17回大阪消化器化学療法懇話会, 大阪, 2018年12月1日.
  52. 古瀬純司 : 特別講演.膵癌化学療法の最新の知見. Pancreatic Cancer and Neuroendocrine tumor FORUM in Chiba, 千葉, 2018年12月14日.
  53. 古瀬純司：消化器癌化学療法の最近の話題-ESMO2018 in Munich. 三鷹キャンサーネット, 三鷹, 2018年12月20日.
  54. 古瀬純司：膵がん治療の最前線－新しいガイドラインと今後の期待. パンキャンジャパン膵がん勉強会クリスマス・スペシャル, 東京, 2018年12月22日.
  55. Chow PKH, Li L, Li J, Jia F, Wang HJ, Hasegawa K, Yang JM, Tan PS, Qin S, Han KH, Goh B, Han HS, Furuse J, Zhu X, Ling JZJ, Gandhi M: Differences in Presentation and Management Patterns in Patients with Hepatocellular Carcinoma (HCC): Data from HCC Registry in Asia. 2019 Gastrointestinal cancers symposium, USA, January 17th-19th,2019.
  56. Kobayashi S, Ueno M, Ogawa G, Fukutomi A, Ikeda M, Okusaka T, Sato T, Ito Y, Kadota T, Ioka T, Sugimori K, Sata N, Nakamori S, Shimizu K, Mizuno N, Ishii H, Furuse J: Impact of renal function on the efficacy and safety of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer: an integrated exploratory analysis of JCOG1106 and LAPC-S1RT. 2019 Gastrointestinal cancers symposium, USA, January 17th-19th, 2019.
  57. Ikeda M, Ueno M, Morizane C, Kobayashi S, Ohno I, Kondo S, Okano N, Kimura K, Asada S, Namba Y, Okusaka T, Furuse J: A multicentre open-label, phase 1 study of nivolumab alone or in combination with gemcitabine plus cisplatin in patients with unresectable or recurrent biliary tract cancer. 2019 Gastrointestinal cancers symposium, USA, January 17th-19th, 2019.
  58. Kudo M, Okusaka T, Motomura K, Ohno I, Morimoto M, Seo S, Wada Y, Sato S, Yamashita T, Furukawa M, Aramaki T, Nadano S, Ohkawa K, Fujii H, Kudo T, Furuse J, Takai H, Homma G, Yoshikawa R, Zhu AX: Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein Following First-Line Sorafenib: Pooled Efficacy and Safety in Japanese Patients Across Two Global Randomized Phase 3 Studies (REACH-2 and REACH). 2019 Gastrointestinal cancers symposium, January 17th-19th, 2019.
  59. Yamada I, Morizane C, Okusaka T, Ogawa G, Sato Y, Ueno M, Ikeda M, Sugimori K, Fukutomi A, Shimizu S, Mizuno N, Yanagimoto H, Sano K, Tobimatsu K, Yane K, Nakamori S, Sata N, Nishina T, Ishii H, Furuse J: The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: An exploratory analysis of JCOG1113. 2019 Gastrointestinal cancers symposium, January 17th-19th, 2019.
  60. Ueno M, Morizane C, Okusaka T, Ogawa G, Sato Y, Ikeda M, Ozaka M, Sugimori K, Fukutomi A, Hara H, Mizuno N, Yanagimoto H, Sano K, Tobimatsu K, Yane K, Nakamori S, Sata N, Nishina T, Ishii H, Furuse J: The influence of renal function on gemcitabine-based chemotherapy for advanced biliary tract cancer: An exploratory analysis of JCOG1113. 2019 Gastrointestinal cancers symposium, January 17th-19th, 2019.
  61. Goyal L, Bahleda R, Furuse J, Valle J, Markus Moehler M, Oh DY, Chang HM, Kelley RK, Javle M, Borad M, Chen LT, Uboha N, Klümpen HJ, O’Dwyer PJ, Li D, Morizane C, Huang J, Bridgewater JA: FOENIX-CCA2 (FOENIX-101): A phase 2 trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions and other rearrangements. 2019 Gastrointestinal cancers symposium, January 17th-19th, 2019.
  62. 長島文夫 : 高齢者のがん治療. 健康長寿講演会（三鷹市老人クラブ連合会）, 三鷹, 2019年2月5日.
  63. 長島文夫 : みんなで支えるがん医療「超高齢社会とがん、杏林CCRC研究所の取り組み」. 杏林CCRCフォーラム公開講演会, 三鷹, 2019年2月23日.
  64. 長島文夫 : 高齢者とがん. 杏林大学講演会シリーズ第7回「がんと共にすこやかに生きる」, 三鷹, 2019年3月2日.
  65. 古瀬純司 : 消化器がんに対するがんゲノム医療. 日本癌治療学会第18回アップデート教育コース, がん治療とゲノム医療, 三鷹, 2019年3月9日.
  66. Furuse J: Consolidating the Treatment Guidelines of Chemotherapy for Cholangiocarcinoma between the East and West. Lecture. 3rd Asian-Pacific Cholangiocarcinoma Conference. Taiwan, March 15th-16th, 2019.
  67. 長島文夫 : 第2回老年腫瘍学セミナー. 日本臨床腫瘍学会,東京, 2019年3月21日.

 

論　文

欧文

  1. Kitahara H1, Honma Y1, Ueno M2, Kanemitsu Y1, Ohkawa S2, Mizusawa J1, Furuse J, Shimada Y3, Colorectal Cancer Study Group and Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (1National Cancer Center Hospital, 2Kanagawa Cancer Center, 3Kochi Health Sciences Center) : Randomized phase III trial of post-operative chemotherapy for patients with stage I/II/III small bowel adenocarcinoma (JCOG1502C, J-BALLAD). Jpn J Clin Oncol, 2018. DOI:10.1093/jjco/hyy188. [Epub ahead of print]
  2. Doi T1, Yoh K1, Shitara K1, Takahashi H1, Ueno M2, Kobayashi S2, Morimoto M2, Okusaka T1, Ueno H1, Morizane C1, Okano N, Nagashima F, Furuse J (1National Cancer Center Hospital East, 2Kanagawa Cancer Center)：First-in-human phase 1 study of novel dUTPase inhibitor TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors. Invest New Drugs, 2018. DOI: 10.1007/s10637-018-069 7-3. [Epub ahead of print]
  3. Shiba S1, Imaoka H2, Shioji K3, Suzuki E4, Horiguchi S5, Terashima T6, Kojima Y7, Okuno T8, Sukawa Y9, Tsuji K10, Umemoto K11, Asagi A12, Todaka A13, Ueno M14, Ikeda M11, Morizane C1, Furuse J（1National Cancer Center Hospital, 2Aichi Cancer Center Hospital, 3Niigata Cancer Center Hospital, 4Chiba University, 5Okayama University Graduate School of Medicine, 6Kanazawa University Hospital, 7National Center for Global Health and Medicine, 8Kinki University, 9Keio University, 10Teine Keijinkai Hospital, 11National Cancer Center Hospital East, 12Shikoku Cancer Center, 13Shizuoka Cancer Center, 14 Kanagawa Cancer Center）：Clinical characteristics of Japanese patients with epithelioid hemangioendothelioma: a multicenter retrospective study. BMC Cancer 18(1) : 993,2018.
  4. Tak WY1, Ryoo BY2, Lim HY3, Kim DY4, Okusaka T5, Ikeda M6, Hidaka H7, Yeon JE8, Mizukoshi E9, Morimoto M10, Lee MA11, Yasui K12, Kawaguchi Y13, Heo J14, Morita S15, Kim TY16, Furuse J, Katayama K17, Aramaki T18, Hara R19, Kimura T19, Nakamura O19, Kudo M20(1Kyungpook National University, 2University of Ulsan College of Medicine, 3Sungkyunkwan University , 4Yonsei University College of Medicine , 5National Cancer Center Hospital, 6National Cancer Center Hospital East , 7Kitasato University Hospital , 8Korea University Guro Hospital , 9Kanazawa University Hospital, 10Kanagawa Cancer Center, 11The Catholic University of Korea, 12Kyoto Prefectural University of Medicine , 13Saga-ken Medical Centre Koseikan , 14Pusan National University and Medical Research Institute , 15Kochi Health Sciences Center , 16Seoul National University Hospital , 17Osaka International Cancer Institute , 18Shizuoka Cancer Center, 19Yakult Honsha , 20Kindai University Hospital )：Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients. Invest New Drugs 36(6) : 1072-1084, 2018.
  5. Mizusawa J1, Fukutomi A2, Katayama H1, Ishii H3, Ioka T4, Okusaka T1, Ueno H1, Ueno M5, Ikeda M6, Mizuno N7, Ozaka M8, Fukuda H1, Furuse J, Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (1National Cancer Center Hospital, 2Shizuoka Cancer Center, Shizuoka, 3National Hospital Organization Shikoku Cancer Center, 4Osaka International Cancer Institute, 5Kanagawa Cancer Center, 6National Cancer Center Hospital East, 7Aichi Cancer Center Hospital, 8Cancer Institute Hospital of the Japanese Foundation for Cancer Research)：Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407). Pancreatology 18(7) : 841-845,2018.
  6. Morizane C1, Ueno M2, Ikeda M3, Okusaka T2, Ishii H4, Furuse J (1National Cancer Center Hospital, 2Kanagawa Cancer Center, 3National Cancer Center Hospital East, 4National Hospital Organization Shikoku Cancer Center)：New developments in systemic therapy for advanced biliary tract cancer. Jpn J Clin Oncol 48(8) : 703-711,2018.
  7. Kobayashi S1, Terashima T2, Shiba S3, Yoshida Y4, Yamada I5, Iwadou S6, Horiguchi S7, Takahashi H8, Suzuki E9, Moriguchi M10, Tsuji K11, Otsuka T12, Asagi A13, Kojima Y14, Takada R15, Morizane C3, Mizuno N16, Ikeda M8, Ueno M1, Furuse J（1Kanagawa Cancer Center, 2Kanazawa University Hospital, 3National Cancer Center Hospital, 4 Shizuoka Cancer Center, 5Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 6Hiroshima City Hospital, 7Okayama University, 8National Cancer Center Hospital East, 9Chiba University, 10Kyoto Prefectural University of Medicine, 11Ishikawa Prefectural Central Hospital, 12Saga University Hospital, 13National Hospital Organization Shikoku Cancer Center, 14National Center for Global Health and Medicine, 15Osaka International Cancer Institute, 16Aichi Cancer Center Hospital）：Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma. Cancer Sci 109(8) : 2549-2557,2018.
  8. Nakachi K1,2, Konishi M1, Ikeda M3, Shimada K3, Okusaka T3, Saiura A4, Ishii H4, Sugiyama M5, Furuse J, Sakamoto H5, Shimamura T5, Ohta T6 (1National Cancer Center Hospital East, 2Otaru General Hospital, 3National Cancer Center Hospital, 4Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 5Saitama Cancer Center, 6Tokyo Women’s Medical University)：Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer. Int J Clin Oncol 23(5) : 894-899,2018.
  9. Sato Y1,2, Ueno H3, Ioka T4, Ohkawa S5, Ikeda M6, Shimamura T7, Tsuji A8, Tsuchiya Y9, Furuse J10, Ishii H11, Furuya K12, Iguchi H13, Saito Y14, Kaniwa N14, Sawada JI14, Sakamoto H1, Sekine A2, Okusaka T3, Yoshida T1(1National Cancer Center Research Institute, 2Chiba University, 3National Cancer Center Hospital, 4Osaka Medical Center for Cancer and Cardiovascular Disease, 5Kanagawa Cancer Center, 6National Cancer Center Hospital East, 7East Medical Clinic, 8Kagawa University, 9Niigata Cancer Center Hospital, 10 Kyorin University, 11Cancer Institute Hospital, 12Hokkaido Social Insurance Hospital, 13Sasebo Kyosai Hospital, 14National Institute of Health Sciences) : GEST. SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated With Gemcitabine, S-1, or Gemcitabine Plus S-1. Pancreas 47(5):637-642，
  10. Furuse J, Shibahara J1, Sugiyama M2(1Department of Pathology, Kyorin university, 2 Department of Surgery, Kyorin university)：Development of chemotherapy and significance of conversion surgery after chemotherapy in unresectable pancreatic cancer. J Hepatobiliary Pancreat Sci 25(5) : 261-268, 2018.
  11. Ozaka M1, Ishii H2, Sato T3, Ueno M4, Ikeda M5, Uesugi K6, Sata N7, Miyashita K8, Mizuno N9, Tsuji K10, Okusaka T10, Furuse J：（1Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 2National Hospital Organization Shikoku Cancer Center, 3Kyoto University School of Public Health, 4Kanagawa Cancer Center, 5National Cancer Center Hospital East, 6Jichi Medical University School of Medicine, 7Showa University Northern Yokohama Hospital, 8Aichi Cancer Center Hospital, 9Ishikawa Prefectural Central Hospital, 10 National Cancer Center Hospital）：A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 81(6) : 1017-1023, 2018.
  12. Natsume M1, Watanabe K1, Matsumoto S2, Naruge D3, Hayashi K4, Furuse J, Kawamura M1, Jinno H1, Sano K1, Fukushima R1, Osawa G1, Aruga E1, Hashiguchi Y1, Tanaka A1, Takikawa H1, Seki N1（1Teikyo University, 2NTT Medical Center Tokyo,3 Kyorin University, 4Tokyo Women’s Medical University）：Factors influencing cancer patients’ choice of end-of-life care place. J Palliat Med 21(6) : 751-765,2018.
  13. Kojima Y1, Ohtsuka K2, Ohnishi H2, Abe N1, Furuse J, Watanabe T2, Sugiyama M1（1 Department of Surgery, Kyorin University, 2Department of Laboratory Medicine, Kyorin Univeresity）：APC:T1556fs and STK11 mutations in duodenal adenomas and adenocarcinomas. Surg Today48(8) : 765-772, 2018.
  14. Suzuki E1, Kaneko S2 Okusaka T3, Ikeda M4, Yamaguchi K5, Sugimoto R6, Aramaki T7, Asagi A8, Yasui K9, Sano K10, Hosokawa A11, Kato N1, Ishii H8, Sato T12, Furuse J（1Chiba University, 2Kanazawa University School of Medical Science, 3National Cancer Center Hospital, 4National Cancer Center Hospital East, 5Saitama Cancer Center, 6Kyushu Cancer Center, 7Shizuoka Cancer Center, 8Shikoku Cancer Center, 9Kyoto Prefectural University of Medicine, 10Teikyo University School of Medicine, 11Faculty of Medicine University of Toyama, 12Kyoto University School of Public Health）: A multicenter Phase II study of sorafenib in Japanese patients with advanced hepatocellular carcinoma and Child Pugh A and B class. Jpn J Clin Oncol 48(4) : 317-321, 2018.
  15. Nakachi K1, Konishi M2, Ikeda M2, Mizusawa J3, Eba J3, Okusaka T3, Ishii H4, Fukuda H3, Furuse J (1Otaru General Hospital, 2National Cancer Center Hospital East, 3National Cancer Center Hospital, 4National Hospital Organization Shikoku Cancer Center)：Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group. A randomized Phase III trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1202, ASCOT). Jpn J Clin Oncol 48(4) : 392-395, 2018.
  • J, Kurata T1, Okano N, Fujisaka Y1, Naruge D, Shimizu T1, Kitamura H, Iwasa T1, Nagashima F, Nakagawa K1(1Kindai University) : An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors. Cancer chemotherapy and pharmacology, 2018.
  1. Sawaki M1, Tamura K2, Shimomura A2, Taki Y1, Nagashima F, Iwata H1(1Aichi Cancer Center Hospital, 2National Cancer Center Hospital) : Practice management for elderly patients with breast cancer: Findings from a survey by the Japan Breast Cancer Study Group. Nagoya Journal of Medical Science.80(2) : 217-26, 2018.
  2. Yamaguchi K1,2, Fujitani K3, Nagashima F, Omuro Y4, Machida N5, Nishina T6, Koue T7, Tsujimoto M7, (1Saitama Cancer Center, 2Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3Osaka General Medical Center, 4Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 5Shizuoka Cancer Center, 6National Hospital Organization Shikoku Cancer Center, 7Eli Lilly Japan, 8Osaka University Hospital)：Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study. Gastric Cancer 21(6) : 1041-9, 2018.
  3. Hamamoto Y1,2, Sakakibara N1, Nagashima F, Kitagawa Y3, Higashi T1 (1National Cancer Center, 2Keio Cancer Center, 3Keio University School of Medicine)： Treatment selection for esophageal cancer: evaluation from a nationwide database. Esophagus15(2) : 109-14, 2018.
  4. Sawaki M1, Tamura K2, Shimomura A2, Taki Y1, Nagashima F, Iwata H1(1Aichi Cancer Center Hospital, 2National Cancer Center Hospital)：Practice management for elderly patients with breast cancer: Findings from a survey by the Japan Breast Cancer Study Group. Nagoya Journal of Medical Science 80(2) : 217-26, 2018.
  5. Furuse J, Kurata T1, Okano N, Fujisaka Y1, Naruge D, Shimizu T1, Kitamura H, Iwasa T1, Nagashima F1, Nakagawa K(1Kindai University Faculty of Medicine) : An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid Cancer Chemother Pharmacol.82(3):511-519, 2018.
  6. Todaka A1, Mizuno N2, Ozaka M3, Ueno H4, Kobayashi S5, Uesugi K6, Kobayashi N7, Hayashi H8, Sudo K9, Okano N, Horita Y10, Kamei K11, Yukisawa S12, Nakamori S13, Yachi Y14, Henmi T15, Kobayashi M16, Boku N1, Mori K1, Fukutomi A1(1Shizuoka Cancer Center, 2Aichi Cancer Center Hospital, 3The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 4National Cancer Center Hospital, 5Kanagawa Cancer Center Hospital, 6National Hospital Organization Shikoku Cancer Center, 7Yokohama City University Hospital, 8Hokkaido University Hospital, 9Chiba Cancer Center,10Toyama Prefectual Central Hospital,11Kindai University Faculty of Medicine, 12Tochigi Cancer Center, 13Osaka National Hospital,14DaiichiSankyo, 15Yakult Honsha,16Shizuoka Industrial Foundation Pharama Vally Center)：Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan. Pancreas47(5):631-636, 2018. DOI: 10.1097/MPA.0000000000001049.
  7. Yoshida T1,2, Hijioka S1,3, Hosoda W1,4, Ueno M5, Furukawa M6, Kobayashi N7, Ikeda M8, Ito T9, Kodama Y10, Morizane C3, Notohara K11, Taguchi H12, Kitano M13, Yane K14, Tsuchiya Y15, Komoto I16, Tanaka H17, Tsuji A18, Hashigo S19, Mine T20, Kanno A21, Murohisa G22, Miyabe K23, Takagi T24, Matayoshi N25, Sakaguchi M26, Ishii H27, Kojima Y28, Matsuo K29, Yoshitomi H30, Nakamori S31, Yanagimoto H32, Yatabe Y33, Furuse J, Mizuno N1 : (1Aichi Cancer Center Hospital, 2Kizawa Memorial Hospital, 3National Cancer Center Hospital, 4The Johns Hopkins University School of Medicine, 5Kanagawa Cancer Center, 6National Kyushu Cancer Center, 7Yokohama City University Hospital, 8National Cancer Center Hospital East, 9Kyushu University, 10Kyoto University, 11Kurashiki Central Hospital, 12Kagoshima University Graduate School of Medical and Dental Sciences, 13Kinki University, 14 Teine-Keijinkai Hospital, 15Niigata Cancer Center Hospital, 16Kansai Electric Power Hospital, 17Suzuka General Hospital, 18 Kobe City Medical Center General Hospital, 19Kumamoto University, 20Tokai University School of Medicine, 21Tohoku University Graduate School of Medicine, 22Seirei Hamamatsu General Hospital, 23Nagoya City University Graduate School of Medical Sciences, 24Fukushima Medical University School of Medicine, 25University of Occupational and Environmental Health, 26Saiseikai Kumamoto Hospital, 27Shikoku Cancer Center, 28Cancer Institute Hospital, 29Center Hospital of the National Center for Global Health and Medicine, 30Aichi Cancer Center Research Institute, 31Chiba University, 32National Hospital Organization Osaka National Hospital, 33Kansai Medical University Hospital)：Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately. Ann Surg Oncol. 26(5):1385-1393, 2019. DOI: 10.1245/s10434-019-07252-8. [Epub ahead of print]
  8. Furuse J: A PARP inhibitor in pancreatic cancer : Enhancement anti-tumour activity of chemoradiation therapy against pancreatic cancer?. EBioMedicine2019. DOI: 10.1016/j.ebiom.2019.01.039.
  9. Yasuda H1, Kataoka K1, Takeyama Y2, Takeda K3, Ito T4, Mayumi T5, Isaji S6, Mine T7, Kitagawa M8, Kiriyama S9, Sakagami J1, Masamune A10, Inui K11, Hirano K12, Akashi R13, Yokoe M14, Sogame Y1, Okazaki K15, Morioka C16, Kihara Y17, Kawa S18, Tanaka M4,Andoh A19, Kimura W20, Nishimori I21, Furuse J, Yokota I22, Shimosegawa T10 (1Kyoto Prefectural University of Medicine, 2Kindai University Faculty of Medicine, 3National Hospital Organization Sendai Medical Center, 4 Kyushu University, 5University of Occupational and Environmental Health, 6Mie University School of Medicine, 7Tokai University School of Medicine, 8Nagoya University of Arts and Sciences, 9Ogaki Municipal Hospital, 10Tohoku University Graduate School of Medicine, 11Fujita Health University Bantane Hospital, 12University of Tokyo, 13Kumamoto Regional Medical Center, 14Japanese Red Cross Nagoya Daini Hospital, 15Kansai Medical University, 16Nara Medical University, 17Kitakyushu General Hospital, 18Matsumoto Dental University, 19Shiga University of Medical Science, 20Yamagata University Faculty of Medicine, 21Kochi Medical School, 22Hokkaido University)：Usefulness of urinary trypsinogen-2 and trypsinogen activation peptide in acute pancreatitis: A multicenter study in Japan. World J Gastroenterol 25(1) : 107-117, 2019.
  10. Motoi F1, Kosuge T2, Ueno H2, Yamaue H3, Satoi S4, Sho M5, Honda G6, Matsumoto I7, Wada K8, Furuse J, Matsuyama Y9, Unno M1, Study Group of Preoperative Therapy for Pancreatic Cancer (Prep) and Japanese Study Group of Adjuvant Therapy for Pancreatic cancer (JSAP) (1Tohoku University School of Medicine, 2National Cancer Center Hospital, 3Wakayama Medical University, 4Kansai Medical University, 5Nara Medical University, 6Tokyo Metropolitan Cancer and Infectious Diseases Center, 7Kindai University Faculty of Medicine, 8Teikyo University School of Medicine, 9University of Tokyo) : Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Jpn J Clin Oncol 49(2) : 190-194, 2019.
  11. Shitara K1, Yamanaka T2, Denda T3, Tsuji Y4, Shinozaki K5, Komatsu Y6, Kobayashi Y7, Furuse J, Okuda H8, Asayama M9, Akiyoshi K10, Kagawa Y11, Kato T12, Oki E13, Ando T14, Hagiwara Y15, Ohashi Y16, Yoshino T1 (1National Cancer Center Hospital East, 2Yokohama City University School of Medicine, 3Chiba Cancer Center, 4Tonan Hospital, 5Hiroshima Prefectural Hospital, 6Hokkaido University Hospital Cancer Center, 7Kushiro Rosai Hospital, 8Keiyukai Sapporo Hospital, 9Saitama Cancer Center, 10Osaka City General Hospital, 11Kansai Rosa Hospital, 12National Hospital Organization Osaka National Hospital, 13Kyushu University, 14University of Tsukuba, 15The University of Tokyo, 16Chuo University)：REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients. Ann Oncol 30(2) : 259-265, 2019.
  12. Ioka T1, Ueno M2, Ueno H3, Park JO4, Chang HM5, Sasahira N6, Kanai M7, Chung IJ8, Ikeda M9, Nakamori S10, Mizuno N11, Omuro Y12, Yamaguchi T13, Hara H14, Sugimori K15, Furuse J, Maguchi H16, Furukawa M17, Fukuzawa K18, Kim JS19, Yukisawa S20, Takeuchi M21, Okusaka T3, Boku N3, Hyodo I22 (1Osaka International Cancer Institute.2Kanagawa Cancer Center, 3National Cancer Center Hospital, 4Sungkyunkwan University School of Medicine, 5University of Ulsan College of Medicine, 6Cancer Institute Hospital of Japanese Foundation for Cancer Research, 7Kyoto University Hospital, 8Chonnam National University Hwasun Hospital, 9National Cancer Center Hospital East, 10National Hospital Organization Osaka National Hospital, 11Aichi Cancer Center Hospital, 12Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 13Chiba Cancer Center,14Saitama Cancer Center Hospital, 15Yokohama City University Medical Center, 16Teine-Keijinkai Hospital, 17National Hospital Organization Kyushu Cancer Center, 18Oita Red Cross Hospital, 19Korea University Guro Hospital, 20Tochigi Cancer Center, 21 Kitasato University, 22 University of Tsukuba)：TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial). Eur J Cancer 106 : 78-88, 2019.
  13. Makishima H1, Yasuda S1, Isozaki Y1, Kasuya G1, Okada N1, Miyazaki M2, Mohamad O1,3, Matsufuji N1, Yamada S1, Tsuji H1, Kamada T1, Liver Cancer Working Group (1National Institute of Radiological Sciences Hospital, 2Mita Hospital, 3University of Texas Southwestern Medical center)：Single fraction carbon ion radiotherapy for colorectal cancer liver metastasis: A dose escalation study. Cancer Sci 110(1) : 303-309,2019.
  14. Denda T1, Sakai D2, Hamaguchi T3, Sugimoto N4, Ura T5, Yamazaki K6 Fujii H7, Kajiwara T8, Nakajima TE9, Takahashi S10, Otsu S11, Komatsu Y12, Nagashima F, Moriwaki T13, Esaki T14, Sato T15, Itabashi M16, Oki E17, Sasaki T18, Sunaga Y18, Ziti-Ljajic S19, Brillac C19, Yoshino T20 (1Chiba Cancer Center, 2 Osaka University Graduate School of Medicine, 3 National Cancer Center Hospital, 4Osaka Medical Center for Cancer and Cardiovascular Disease, 5Aichi Cancer Center Hospital, 6Shizuoka Cancer Center, 7Jichi Medical University Hospital, 8Shikoku Cancer Center, 9 Marianna University School of Medical Hospital, 10Tohoku University Hospital, 11Oita University Hospital, 12Hokkaido University Hospital, 13University of Tsukuba Hospital, 14National Kyushu Cancer Center, 15Kitasato University East Hospital, 16Tokyo Women’s Medical University Hospital, 17Kyushu University Hospital, 18Sanofi K. K, 19Sanofi Oncology, 20National Cancer Center Hospital East) : Phase II trial of aflibercept with FOLFIRI as a second-line treatment , for Japanese patients with metastatic colorectal cancer. Cancer science, 2019.
  15. Shirasu H1, Todaka A1, Omae K2, Fujii H3, Mizuno N4, Ozaka M5, Ueno H6, Kobayashi S7, Uesugi K8, Kobayashi N9, Hayashi H10, Sudo K11, Okano N, Horita Y12, Kamei K13, Yukisawa S14, Kobayashi M15, Fukutomi A16 (1Shizuoka Cancer Center, 2Jichi Medical University Hospital, 3Aichi Cancer Center Hospital, 4The Cancer Institute Hospital of the Japanese Foundation For Cancer Research, 5National Cancer Center Hospital, 6Kanagawa Cancer Center, 7 National Hospital Organization Shikoku Cancer Center, 8Yokohama City University Hospital, 9 Hokkaido University Graduate School of Medicine, 10Chiba Cancer Center, 11Toyama Prefectural Central Hospital, 12 Kindai University, 13Tochigi Cancer Center, 14 Shizuoka Industrial Foundation Pharma Valley Center) : Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX. Cancer Sci110(2) : 707-716, 2019. DOI: 10.1111, /cas.13883.

和文

  1. 北村浩1, 井戸田一朗1, 岡山香里2, 大河戸光章3, 佐野彰彦4, 佐野麻里子5, 小林治6, 河合伸4, 古瀬純司 (1しらかば診療所, 2群馬バース大・保・検査技術学, 3杏林大・保・ 臨床検査技術学, 4杏林大・医・総合医療学・5杏林大・医学部付属病院看護部, 6杏林大・保) : 拡大肛門鏡検査によるHIV陽性者の肛門管上皮内病変の診断と治療. 日本エイズ学会誌 20(1) : 25-31, 2018.
  2. 古瀬純司 : 切除不能膵癌に対する化学療法. 消化器外科 41(6):911-917, 2018.
  3. 古瀬純司 : 化学療法. 膵癌 臨牀消化器内科 33(7):167-173, 2018.
  4. 古瀬純司 : 切除不能膵癌に対する化学療法―現状と今後の展望. 癌の臨床 64(1) : 17-23, 2018.
  5. 古瀬純司 : 膵癌の治療. 化学療法と化学放射線療法. Current Therapy 36(6):23-28, 2018.
  6. 古瀬純司 : 急激に変貌する肝癌の薬物療法.免疫チェックポイント阻害薬（単剤）. Liver Cancer Journal 10(1):44-48, 2018.
  7. 古瀬純司 : 膵神経内分泌腫瘍の化学療法. 臨牀消化器内科 33(9):1177-1182, 2018.
  8. 古瀬純司 : 進行肝細胞癌に対する分子標的治療のオーバービュー. 消化器・肝臓内科 4(1):37-43, 2018.
  9. 古瀬純司 : Cabozantinibの第II相試験の振り返りと第III総試験結果. 肝胆膵 77(2):393-397, 2018.
  10. 古瀬純司 : ソラフェニブ不応進行肝細胞癌に対するレゴラフェニブの第Ⅲ相試験（RESORCE）の示唆すること. がん分子標的治療 16(3):78-81, 2018.
  11. 山内芳也, 長島文夫, 河合桐男, 岡野尚弘, 成毛大輔, 小林敬明, 古瀬純司：高齢がん患者の機能評価. 外科と代謝・栄養 52(1):17-22, 2018.
  12. 小林敬明, 前野聡子, 長島文夫：高齢者のがん診療〜実地医家の視点から〜 胃がん・大腸がん. 内科 121(4):887-891, 2018.
  13. 前野聡子, 長島文夫：がんとフレイル. 最新医学　別冊(フレイル):107-112, 2018.
  14. 前野聡子, 長島文夫：老年医学領域の高度医療・未来医療　高齢者のがん医療の進歩. 日本臨床76(増刊5 老年医学(上)):255-259, 2018.
  15. 岡野尚弘, 黒澤貴志, 西岡真理子, 前園知宏, 河合桐男, 小林敬明,長島文夫, 古瀬純司 : 切除不能胆道癌に対する二次治療　現状と今後の期待. 胆と膵39(10):869-874, 2018.
  16. 黒澤貴志, 前野聡子, 長島文夫：後期高齢者に対するがん薬物治療の問題点. 臨床腫瘍プラクティス 14(4):241-248, 2018.
  17. 長島文夫, 小林智1, 柳本泰明2, 中井陽介3(1神奈川県立がんセンター・消化器内科, 2関西医大・医・外科学講座, 3東京大・医・消化器内科)：膵・胆道癌高齢患者に対する積極的抗癌治療. 膵・胆道癌Frontier 7(2):64-71, 2018.
  18. 黒澤貴志, 岡野尚弘, 長島文夫, 古瀬純司 : 胆嚢癌の治療. 消化器内科 34(2):193-198, 2019.
  19. 古瀬純司 : 膵癌の予後改善に向けて. 医学のあゆみ 268(11):893, 2019.
  20. 岡野尚弘, 西岡真理子, 前園知宏, 黒澤貴志, 河合桐男, 小林敬明, 長島文夫, 古瀬純司 : 大腸がん化学療法の最近の潮流. 消化器・肝臓内科 5(1):1-9, 2019.
  21. 岡野尚弘：41st ESMO Congress 2016. 膵胆道癌FRONTIER 7(1):43-44, 2019.
  22. 岡野尚弘：切除不能膵癌に対するconversion surgery. 医学のあゆみ268(11):913-916, 2019.
  23. 前野聡子, 河合桐男, 黒澤貴志, 西岡真理子, 前園知宏, 北村浩, 小林敬明, 岡野尚弘, 長島文夫, 古瀬純司 : 高齢者に対する大腸癌化学療法の実際. 消化器・肝臓内科5(1):17-23, 2019.
  24. 前野聡子,長島文夫 ：高齢がん診療のあり方. Geriatric　Neurosurgery31：19-22, 2019.

 

著書

  1. 河合桐男,古瀬純司（分担執筆）: IV.　薬剤のマネージメント エベロリムス. 膵・消化管NETの診断と治療レジメン―治療に困った時に必ず役に立つ！―. 肱岡範, 奥坂拓志編集. 東京, 医学と看護社, 2018. p.92-96.
  2. 古瀬純司（分担執筆）:　肝癌, 胆道癌, 膵癌化学療法の最近の動向. エビデンスに基づいた癌化学療法ハンドブック 大津敦編集. 大阪, メディカルレビュー社, 2018. p.478-490.

 

 

 

 

  1. 岡野尚弘（分担執筆）: 膵癌　 エビデンスに基づいた癌化学療法ハンドブック2018. 大津敦編集. 大阪, メディカルレビュー社, 2018. p.511-513
  2. 岡野尚弘（分担執筆）: 膵癌　GEM＋Nab-PTX. エビデンスに基づいた癌化学療法ハンドブック 大津敦編集. 大阪, メディカルレビュー社, 2018. p.514-516
  3. 岡野尚弘（分担執筆）: 膵癌　GEM＋ エビデンスに基づいた癌化学療法ハンドブック2018. 大津敦編集. 大阪, メディカルレビュー社, 2018. p.521-523
  4. 岡野尚弘（分担執筆）： 大腸癌　UFT＋ 消化器がん化学療法レジメンブック4版. 室圭編著. 東京, 日本医事新報社, 2018. p.191-193.
  5. 岡野尚弘（分担執筆）： 大腸癌　IRI＋S-1/IRIS療法＋ベバシズマブ. 消化器がん化学療法レジメンブック4版. 室圭編著. 東京, 日本医事新報社, 2018. p.194-197.
  6. 古瀬純司（分担執筆）: ガイドライン外来診療膵癌. 東京, 日経メディカル開発, 2019. p.585-589.
  7. 古瀬純司（編者）: がん化学療法の薬－抗がん剤・ホルモン剤・分子標的薬・免疫チェックポイント阻害薬・支持療法薬－はや調べノート2019・2020年版. がんナーシング. 大阪, メディカ出版，
  8. 古瀬純司（編者）: 膵癌の予後改善に向けて.医学のあゆみ.東京,医歯葉出版, 268(11), 2019
  9. 古瀬純司（編者）: 神経内分泌腫瘍の薬物療法.東京, 科学評論社, 23(3), 2019
  10. 岡野尚弘（分担執筆）: レゴラフェニブ. がん化学療法の薬－抗がん剤・ホルモン剤・分子標的薬・免疫チェックポイント阻害薬・支持療法薬－はや調べノート2019・2020年版. がんナーシング. 古瀬純司編集. 大阪, メディカ出版, 2019. p.58-59.
  11. 岡野尚弘（分担執筆）: バンデタニブ. がん化学療法の薬－抗がん剤・ホルモン剤・分子標的薬・免疫チェックポイント阻害薬・支持療法薬－はや調べノート2019・2020年版. がんナーシング. 古瀬純司編集. 大阪, メディカ出版, 2019. p.60-61.
  12. 岡野尚弘（分担執筆）: ゲムシタビン.化学療法の薬－抗がん剤・ホルモン剤・分子標的薬・免疫チェックポイント阻害薬・支持療法薬－はや調べノート2019・2020年版. がんナーシング. 古瀬純司編集. 大阪, メディカ出版, 2019. p.142-143.
  13. 岡野尚弘（分担執筆）: パクリタキセル. がん化学療法の薬－抗がん剤・ホルモン剤・分子標的薬・免疫チェックポイント阻害薬・支持療法薬－はや調べノート2019・2020年版. がんナーシング. 古瀬純司編集. 大阪, メディカ出版, 2019. p.230-231.
  14. 岡野尚弘（分担執筆）: ナブパクリタキセル. がん化学療法の薬－抗がん剤・ホルモン剤・分子標的薬・免疫チェックポイント阻害薬・支持療法薬－はや調べノート2019・2020年版. がんナーシング. 古瀬純司編集. 大阪, メディカ出版, 2019. p.232-233.
  15. 岡野尚弘（分担執筆）: ドセタキセル. がん化学療法の薬－抗がん剤・ホルモン剤・分子標的薬・免疫チェックポイント阻害薬・支持療法薬－はや調べノート2019・2020年版. がんナーシング. 古瀬純司編集. 大阪, メディカ出版, 2019. p.234-235.
© 2021 Kyorin University All rights reserved.